theratech.com - THTX Business Value to Revenue

Risks of a narrow distribution channel and expensive borrowing limit the growth of Theratechnologies Inc. (THTX), as confirmed by the EV/Sales multiple history. Meanwhile, the brand is valued for its HIV therapy efficacy, and its potential is expanding through oncology developments. The mark serves as a current indicator demonstrating real demand for the asset, accounting for the debt load and cost inflation.
Financial and market metric breakdowns for Theratechnologies (THTX)

Fundamental asset screening begins with an analysis of a business's market value relative to its operating income. The current EV/Revenue ratio reflects the relationship between the total enterprise value and sales volume, excluding the impact of the debt structure. An increase in this metric signals overvaluation, while a decrease suggests potential undervaluation. For Theratechnologies Inc. (THTX), stable demand for HIV drugs smooths the volatility of this indicator, although oncology development costs limit profitability growth.